AI Takes on The World of Medicament, Influencing Drug Development

by May 7, 2019 0 comments

Artificial Intelligence

British-Swedish pharmaceutical company AstraZeneca declared a long-term alliance with a UK-based firm BenevolentAI to combine computational medicine and advanced AI technology. Both companies will focus on employing AI/ML to discover and develop novel drugs for CKD (Chronic Kidney Diseases) and IPF (Idiopathic Pulmonary Fibrosis).

Mene Pangalo, AstraZeneca’s executive vice president and president BioPharmaceuticals R&D said, “The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca’s disease area expertise and large, diverse datasets with BenevolentAI’s leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases.”

The deal is the most recent and significant AI collaboration declaration in the biopharma industry. Additionally, Concerto HealthAI had signed a deal with Bristol Myers Squibb after which it signed a similar deal with Pfizer in early April. In this particular deal, the commonality between the companies is that – Concerto focuses on oncology-specific real-world data and advanced Artificial Intelligence for real-world evidence generation.

On the other hand, Concerto HealthAI in alliance with Pfizer will focus on Precision Oncology using former’s Eureka Health Platform, AI models and real-world clinical electronic medical record and healthcare claims. This collaboration is expected to employ data from clinical medical practices that take part in the American Society of Clinical Oncology’s CancerLinQ initiative.

Also, in March 2019, a biopharmaceutical company Oxford Biomedica revealed that it had signed a two-year research and development deal with Microsoft Research. The alliance aims at improving the yield and quality of next-gen genes therapy vectors using AI and ML.

Notably, Oxford Biomedica will work on its expertise in vector development and large-scale manufacturing. The team at Microsoft will employ AI/ML technology to accelerate the yield and improve the purity of Biomedica’s lentiviral vectors while reducing the costs.

No Comments so far

Jump into a conversation

No Comments Yet!

You can be the one to start a conversation.

Your data will be safe!Your e-mail address will not be published. Also other data will not be shared with third person.